MA27618A1 - Utilisation des antagonistes du recepteur b2 de la bradykinine pour le traitement de l'osteo-arthrose - Google Patents

Utilisation des antagonistes du recepteur b2 de la bradykinine pour le traitement de l'osteo-arthrose

Info

Publication number
MA27618A1
MA27618A1 MA28425A MA28425A MA27618A1 MA 27618 A1 MA27618 A1 MA 27618A1 MA 28425 A MA28425 A MA 28425A MA 28425 A MA28425 A MA 28425A MA 27618 A1 MA27618 A1 MA 27618A1
Authority
MA
Morocco
Prior art keywords
bradykinin
arthrosis
osteo
treatment
diseases
Prior art date
Application number
MA28425A
Other languages
English (en)
Inventor
Martin Michaelis
Karl Rudolphi
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA27618A1 publication Critical patent/MA27618A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/043Kallidins; Bradykinins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Les peptides à effet antagoniste de la bradykinine sont adaptés à la préparation de médicaments pour le traitement prophylactique et thérapeutique de maladies dont le développement est en partie dû à l'activité accrue de métalloprotéinases matricielles. Font partie de ces maladies les maladies articulaires dégénératives, par exemple l'ostéoarthrose et la spondylose, l'atrophie du cartilage suite à une lésion articulaire ou à une position de repos prolongée de l'articulation après lésion d'un ménisque ou d'une rotule ou bien des déchirures ligamentaires.
MA28425A 2003-02-07 2005-08-05 Utilisation des antagonistes du recepteur b2 de la bradykinine pour le traitement de l'osteo-arthrose MA27618A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10304994A DE10304994A1 (de) 2003-02-07 2003-02-07 Die Verwendung von Antagonisten des Bradykinin-B2 Rezeptors zur Behandlung von Osteoarthrose

Publications (1)

Publication Number Publication Date
MA27618A1 true MA27618A1 (fr) 2005-11-01

Family

ID=32797325

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28425A MA27618A1 (fr) 2003-02-07 2005-08-05 Utilisation des antagonistes du recepteur b2 de la bradykinine pour le traitement de l'osteo-arthrose

Country Status (30)

Country Link
EP (1) EP1594520B1 (fr)
JP (1) JP2006516980A (fr)
KR (1) KR20050105447A (fr)
CN (1) CN1317029C (fr)
AR (1) AR043036A1 (fr)
AT (1) ATE335500T1 (fr)
AU (1) AU2004210396A1 (fr)
BR (1) BRPI0407333A (fr)
CA (1) CA2514152C (fr)
CO (1) CO5690613A2 (fr)
CY (1) CY1105708T1 (fr)
DE (2) DE10304994A1 (fr)
DK (1) DK1594520T3 (fr)
ES (1) ES2268622T3 (fr)
HR (1) HRP20050701B1 (fr)
IL (1) IL169899A0 (fr)
MA (1) MA27618A1 (fr)
ME (1) MEP41008A (fr)
MX (1) MXPA05007310A (fr)
MY (1) MY135827A (fr)
NO (1) NO333903B1 (fr)
NZ (1) NZ541680A (fr)
PE (1) PE20040939A1 (fr)
PL (1) PL206412B1 (fr)
PT (1) PT1594520E (fr)
RS (1) RS51029B (fr)
RU (1) RU2329057C2 (fr)
TW (1) TW200505472A (fr)
WO (1) WO2004069266A2 (fr)
ZA (1) ZA200505177B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0710522D0 (en) * 2007-06-01 2007-07-11 Royal Veterinary College The Drug delivery system comprising matrix metalloproteinase inhibitors
IT1391236B1 (it) * 2008-07-11 2011-12-01 St Luso Farm D'italia Spa Composizioni farmaceutiche a base di antagonisti del recettore b2 delle chinine e corticosteroidi e loro uso

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63490B1 (en) * 1988-11-24 1995-05-03 Hoechst Ag Peptides having bradykinin antagonist action
MX9100717A (es) * 1990-08-24 1992-04-01 Syntex Inc Antagonistas de la bradiquinina
FR2751650B1 (fr) * 1996-07-24 1998-10-09 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
FR2751878B1 (fr) * 1996-07-30 1998-09-04 Oreal Utilisation dans une composition d'un extrait d'au moins une labiee
US6346519B1 (en) * 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
CA2364178C (fr) * 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl-l-prolines utilisees comme antagonistes de la bradykinine
AU2003212898B2 (en) * 2002-02-01 2008-10-02 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation

Also Published As

Publication number Publication date
BRPI0407333A (pt) 2006-01-10
HRP20050701A2 (en) 2006-09-30
NO333903B1 (no) 2013-10-14
RU2005127862A (ru) 2006-01-27
WO2004069266A3 (fr) 2004-09-30
IL169899A0 (en) 2011-08-01
HRP20050701B1 (hr) 2014-01-03
CN1317029C (zh) 2007-05-23
ES2268622T3 (es) 2007-03-16
NO20054144L (no) 2005-09-06
JP2006516980A (ja) 2006-07-13
AU2004210396A1 (en) 2004-08-19
RU2329057C2 (ru) 2008-07-20
CO5690613A2 (es) 2006-10-31
CA2514152A1 (fr) 2004-08-19
RS51029B (sr) 2010-10-31
AR043036A1 (es) 2005-07-13
EP1594520B1 (fr) 2006-08-09
EP1594520A2 (fr) 2005-11-16
MXPA05007310A (es) 2005-09-30
PL206412B1 (pl) 2010-08-31
KR20050105447A (ko) 2005-11-04
MEP41008A (en) 2011-02-10
CN1747742A (zh) 2006-03-15
DK1594520T3 (da) 2006-12-11
MY135827A (en) 2008-07-31
ATE335500T1 (de) 2006-09-15
ZA200505177B (en) 2006-11-29
PT1594520E (pt) 2006-11-30
CA2514152C (fr) 2012-01-17
NZ541680A (en) 2009-07-31
CY1105708T1 (el) 2010-12-22
PL376605A1 (pl) 2006-01-09
HK1085926A1 (en) 2006-09-08
WO2004069266A2 (fr) 2004-08-19
TW200505472A (en) 2005-02-16
DE502004001159D1 (de) 2006-09-21
RS20050565A (sr) 2007-09-21
DE10304994A1 (de) 2004-09-02
PE20040939A1 (es) 2005-01-17

Similar Documents

Publication Publication Date Title
BR0114410A (pt) Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
BR0010138A (pt) Moduladores de receptores de glucocorticóides
AR035828A1 (es) Abridor de canal k activado por calcio de gran conductancia, uso del mismo o de un compuesto de azol sustituido para preparar un medicamento, compuesto de azol sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
WO2003106452A3 (fr) Antagonistes du recepteur de l'hormone de melano-concentration
BR9915943A (pt) Formulação de liberação controlada compreendendo gnrh-ii
MA28660B1 (fr) Composes et compositions en tant que modulateurs de ppar
BR9814435A (pt) Novos esteróides antiestrogênicos e composições farmacêuticas associadas
HU9603228D0 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
EP2037739A4 (fr) Effecteurs allostériques positifs du récepteur m1 à base de quinolone à substitution benzyle
TNSN02018A1 (fr) COMPOSITIONS COMPRENANT UN AGONISTE INVERSE DE GABAa, ET UN AGONISTE PARTIEL DES RECEPTEURS DE NICOTINE, UN OESTROGENE, UN MODULATEUR SELECTIF DES RECEPTEURS D'OESTROGENE OU DE LA VITAMINE E
TNSN97044A1 (fr) Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.
CA2360313A1 (fr) Modulateurs selectifs de recepteur de glucocorticoide
BR0209662A (pt) Método para o tratamento e/ou profilaxia de condições caracterizadas pela função alterada de instestino e/ou dor visceral em seres humanos ou mamìferos não humanos
FR06C0032I2 (fr) Formulations proteiniques
FR2784899B1 (fr) Agoniste, agoniste partiel ou antagoniste du recepteur 5-ht4 ou un sel pharmaceutiquement acceptable de ceux-ci pour utilisation dans la fabrication d'une composition pharmaceutique, y compris a usage veterinaire
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
MA27618A1 (fr) Utilisation des antagonistes du recepteur b2 de la bradykinine pour le traitement de l'osteo-arthrose
BR0209290A (pt) Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh
MX2007004199A (es) Derivados de indol sustituidos con 5-sulfonil-1-piperidinil como antagonistas del receptor 5-ht6 para el tratamiento de trastornos del cns.
GT200400068A (es) Derivados de 3-azabiciclo[3.2.1]octano
WO2002013763A3 (fr) Traitement de l'infection par vih-1 et de maladies inflammatoires au moyen d'antagonistes du recepteur de la cyclophiline
BRPI0408956A (pt) emprego de derivativos de carbamazepina para o tratamento de agitação em pacientes com demência
BR0312943A (pt) Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib
Schott The idiopathic dystonias. A note on their orthopaedic presentation
BR0009327A (pt) Composição farmacêutica para a terapia de sintomas do trato urinário inferior